Flores-Santibáñez, F.Cuadra, B.Fernández, D.Rosemblatt, M.V.Núñez, S.Cruz, P.Gálvez-Cancino, F.César Cárdenas, J.Lladser, A.Rosemblatt, M.Bono, M.R.Sauma, D.2018-08-212018-08-212018-02Frontiers in Immunology, 9(FEB), art. no. 209.1664-3224DOI: 10.3389/fimmu.2018.00209http://repositorio.unab.cl/xmlui/handle/ria/6727Indexación: Scopus.Memory CD8+ T cells are ideal candidates for cancer immunotherapy because they can mediate long-term protection against tumors. However, the therapeutic potential of different in vitro-generated CD8+ T cell effector subsets to persist and become memory cells has not been fully characterized. Type 1 CD8+ T (Tc1) cells produce interferon-γ and are endowed with high cytotoxic capacity, whereas IL-17-producing CD8+ T (Tc17) cells are less cytotoxic but display enhanced self-renewal capacity. We sought to evaluate the functional properties of in vitro-generated Tc17 cells and elucidate their potential to become long lasting memory cells. Our results show that in vitro-generated Tc17 cells display a greater in vivo persistence and expansion in response to secondary antigen stimulation compared to Tc1 cells. When transferred into recipient mice, Tc17 cells persist in secondary lymphoid organs, present a recirculation behavior consistent with central memory T cells, and can shift to a Tc1 phenotype. Accordingly, Tc17 cells are endowed with a higher mitochondrial spare respiratory capacity than Tc1 cells and express higher levels of memory-related molecules than Tc1 cells. Together, these results demonstrate that in vitro-generated Tc17 cells acquire a central memory program and provide a lasting reservoir of Tc1 cells in vivo, thus supporting the use of Tc17 lymphocytes in the design of novel and more effective therapies.enCD8+ T cell memoryHomingOxidative metabolismPersistenceSecondary expansionTc17 cellsArtículo